Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26

BIOGEN INC.

Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.
GAAP and non-GAAP diluted EPS impact of approximately ($0.26) per share.
Charge covers upfront and milestone payments from collaboration/license agreements.
Biogen does not forecast such expenses due to uncertainty in timing and magnitude.
Q2 2025 results not finalized; subject to closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.